Cythera Inc., of San Diego, named Michael Ross CEO and Lutz Giebel chief operating officer.

CytoTherapeutics Inc., of Sunnyvale, Calif., named George Dunbar acting president and CEO.

Demegen Inc., of Pittsburgh, appointed Elizabeth Spencer project manager.

Eligix Inc., of Medford, Mass., named David Cook senior vice president of research and development.

Eos Biotechnology Inc., of South San Francisco appointed John Whelan vice president and chief financial officer and Anne Titterton vice president, legal and general counsel.

Genometrix Inc., of The Woodlands, Texas, named to its scientific advisory board Teruhisa Noguchi, president and CEO of Tenox Institute, and Yasufumi Murakami, a professor of genomics at the Laboratory of Genome Biology at the Science University of Tokyo.

HeavenlyDoor.com Inc., of Cambridge, Mass., named to its board of directors Philip Pauze, president of Pauze Swanson Capital Management Co.; Howard Weiser, the company's founder; and Richard Kurtz, owner of Kamson Corp.

Immunomedics Inc., of Morris Plains, N.J., appointed to its board of directors Morton Coleman, a clinical professor of medicine and director of the Center for Lymphoma and Myeloma in the Division of Hematology-Oncology at New York Presbyterian Hospital-Cornell Medical Center.

Inhibitex Inc., of Alpharetta, Ga., appointed as chairman Carl Brooks, president of Brooks & Associates, a management consulting firm. It also elected as a director Richard Schneider, retired partner of Domain Associates Inc.

InterMune Pharmaceuticals Inc., of Palo Alto, Calif., hired Christine Czarniecki as vice president of regulatory affairs.

Kiva Genetics Inc., of Mountain View, Calif., hired Steven Lehrer as chief business officer.

Matrix Pharmaceutical Inc., of Fremont, Calif., named to its board of directors Stephen Howell, a professor of medicine at the University of California, San Diego.

Neuron Therapeutics Inc., of Malvern, Pa., named Timothy Pelura vice president of research and development and David Hesson director of drug development.

PathoGenesis Corp., of Seattle, named Dinu Sen senior vice president of sales and marketing.

Procyon BioPharma Inc., of Montreal, appointed to its board of directors Bernard Coupal, president of T₂C₂.

Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., promoted Kenneth Surowitz to vice president of regulatory affairs and quality.

SafeScience Inc., of Boston, named John Burns chief financial officer.

Telik Inc., of South San Francisco, appointed to its board of directors David Bethune, CEO of Atrix Laboratories Inc.

Xanthon Inc., of Research Triangle Park, N.C., named Neil Moore director of business development.

Xenova Group plc, of Slough, UK, appointed Peter Gillett a non-executive director.